Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.
Open Access
- 1 December 1995
- Vol. 37 (6) , 811-818
- https://doi.org/10.1136/gut.37.6.811
Abstract
No reliable identification of quiescent Crohn's disease (CD) patients with a high risk of relapse is available. The aim of this study was to develop a prognostic index to identify those patients. Untreated adult patients with quiescent disease (not induced by surgery) included in three phase III clinical trials were analysed retrospectively with respect to time to relapse. Nineteen factors related to biology, disease history, and topography were investigated. A relapse was defined as either a CD Activity Index (CDAI) > or = 200, a CDAI > or = 150 but over the baseline value by more than 100, or acute complications requiring surgery. The inclusion criteria were fulfilled by 178 patients. The median follow up was 23 months. The Cox model retained the following bad prognostic factors: age < or = 25 years, interval since first symptoms > 5 years, interval since previous relapse < or = 6 months, and colonic involvement (p < 0.001). Bootstrapping confirmed the variable selection. Patients were classified into three groups with an increasing risk of relapse (p < 0.001). The worst risk group was composed of patients presenting at least three of the four bad prognostic factors. These results make possible the design of clinical trials in quiescent CD patients with a high risk of relapse.Keywords
This publication has 28 references indexed in Scilit:
- Practical problems in fitting a proportional hazards model to data with udated measurements of the covariatesStatistics in Medicine, 1994
- Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's diseaseGastroenterology, 1992
- Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital.Gut, 1990
- Coated oral 5‐aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's diseaseAlimentary Pharmacology & Therapeutics, 1990
- Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).Gut, 1989
- Predicting relapses of Crohn's diseaseDigestive Diseases and Sciences, 1987
- Predictors of acute relapse of Crohn's diseaseDigestive Diseases and Sciences, 1987
- European Cooperative Crohn’s Disease Study (ECCDS): Clinical Features and Natural HistoryDigestion, 1984
- Morbus CrohnDeutsche Medizinische Wochenschrift (1946), 1978
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958